Immunovant Inc IMVT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Roivant Provides Update on Graves’ Disease Development Program
-
Immunovant Provides Update on Graves’ Disease Development Program
-
Immunovant to Host Graves’ Disease Program Update on September 9, 2024
-
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024
-
Immunovant Gets Positive Data From Graves' Disease Treatment Trial
Trading Information
- Previous Close Price
- $29.28
- Day Range
- $29.53–30.66
- 52-Week Range
- $24.67–45.58
- Bid/Ask
- $30.02 / $30.80
- Market Cap
- $4.47 Bil
- Volume/Avg
- 762,855 / 980,106
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 207
- Website
- https://www.immunovant.com
Comparables
Valuation
|
Metric
|
IMVT
|
ACLX
|
ARTV
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 7.86 | 8.39 | — |
Price/Sales | — | 26.80 | 4.27 |
Price/Cash Flow | — | 493.86 | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IMVT
|
ACLX
|
ARTV
|
|---|---|---|---|
Quick Ratio | 12.49 | 5.85 | 4.43 |
Current Ratio | 13.08 | 6.01 | 4.59 |
Interest Coverage | — | −28.35 | — |
Quick Ratio
IMVT
ACLX
ARTV
Profitability
|
Metric
|
IMVT
|
ACLX
|
ARTV
|
|---|---|---|---|
Return on Assets (Normalized) | −45.56% | −1.88% | −16.21% |
Return on Equity (Normalized) | −49.69% | −3.31% | — |
Return on Invested Capital (Normalized) | −54.28% | −7.10% | — |
Return on Assets
IMVT
ACLX
ARTV
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Dsyqhmfmsm | Tvlzd | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jfwgxpzv | Flbxbq | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bsjslhzw | Jrypqr | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dmrhbrzz | Qqnpyhg | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Svjwfkxrv | Dsd | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Qpljyrs | Cvyt | $28.5 Bil | |||
| Moderna Inc
MRNA
| Lfpdpjnw | Dblf | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Cqxfrhp | Tpsxv | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Spwrrddzn | Zdghg | $13.0 Bil | |||
| Incyte Corp
INCY
| Rnlhvfms | Gtkhhcl | $12.9 Bil |
United States